Raymond James & Associates lowered its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 6.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,079,536 shares of the medical research company’s stock after selling 74,674 shares during the period. […]
Transcend Capital Advisors LLC reduced its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,501 shares of the medical research company’s stock after selling 101 shares during the […]
Fulton Breakefield Broenniman LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 10.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,313 shares of the medical research company’s stock after selling 821 shares during the period. Fulton […]
Fulton Breakefield Broenniman LLC lessened its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 10.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,313 shares of the medical research company’s stock after selling 821 shares during the quarter. Fulton […]
Consolidated Planning Corp bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 728 shares of the medical research company’s stock, valued at approximately $210,000. Several other institutional investors and […]